These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 31559249)
61. Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin. Stevens NE; Cowin AJ; Kopecki Z Front Immunol; 2019; 10():1089. PubMed ID: 31156638 [TBL] [Abstract][Full Text] [Related]
67. Current treatment of autoimmune blistering diseases. Kasperkiewicz M; Schmidt E Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595 [TBL] [Abstract][Full Text] [Related]
68. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology. Santi CG; Gripp AC; Roselino AM; Mello DS; Gordilho JO; Marsillac PF; Porro AM An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):33-47. PubMed ID: 31166405 [TBL] [Abstract][Full Text] [Related]
69. Retrospective Study on Autoimmune Blistering Disease in Paediatric Patients. Kong YL; Lim YL; Chandran NS Pediatr Dermatol; 2015; 32(6):845-52. PubMed ID: 26391853 [TBL] [Abstract][Full Text] [Related]
71. Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. Mulyowa GK; Jaeger G; Kabakyenga J; Bröcker EB; Zillikens D; Schmidt E Int J Dermatol; 2006 Sep; 45(9):1047-52. PubMed ID: 16961507 [TBL] [Abstract][Full Text] [Related]
72. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. Bertram F; Bröcker EB; Zillikens D; Schmidt E J Dtsch Dermatol Ges; 2009 May; 7(5):434-40. PubMed ID: 19170813 [TBL] [Abstract][Full Text] [Related]
73. Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment. Kartan S; Shi VY; Clark AK; Chan LS Am J Clin Dermatol; 2017 Feb; 18(1):105-126. PubMed ID: 27878477 [TBL] [Abstract][Full Text] [Related]
74. Recent progress in studies on autoantigens for various autoimmune blistering skin diseases. Hashimoto T Keio J Med; 1995 Dec; 44(4):115-23. PubMed ID: 8587223 [TBL] [Abstract][Full Text] [Related]
75. A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita. Patel PM; Jones VA; Murray TN; Amber KT Am J Clin Dermatol; 2020 Aug; 21(4):557-565. PubMed ID: 32180161 [TBL] [Abstract][Full Text] [Related]
76. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Jolles S Clin Exp Dermatol; 2001 Mar; 26(2):127-31. PubMed ID: 11298100 [TBL] [Abstract][Full Text] [Related]
79. Unusual subepidermal bullous diseases with immunologic features of bullous pemphigoid. Provost TT; Maize JC; Ahmed AR; Strauss JS; Dobson RL Arch Dermatol; 1979 Feb; 115(2):156-60. PubMed ID: 371547 [TBL] [Abstract][Full Text] [Related]
80. The Significance of Scalp Involvement in Pemphigus: A Literature Review. Sar-Pomian M; Rudnicka L; Olszewska M Biomed Res Int; 2018; 2018():6154397. PubMed ID: 29770335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]